Emergency treatment of broncial obstruction diseases in outpatient practice
https://doi.org/10.21518/2079-701X-2013-11-50-53
Abstract
The most widespread bronchial obstruction diseases are bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD). Exacerbations of asthma and COPD are typically accompanied by acute bronchial obstruction syndrome (BOS). It is common knowledge that first-line drugs in the emergency care of patients with acute BOS are short-acting bronchodilators and glucocorticoids. Short-acting bronchodilators are used in the treatment of exacerbations, to prevent risk of exacerbation or as a symptomatic treatment of BA and COPD, in accordance with clinical and functional symptoms and the course of the disease (controlled, partly controlled, uncontrolled BA) [1] .
About the Author
I. V. Leschenko
Ural State Medical University, Russia's Ministry of Health, Yekaterinburg
Russian Federation
Russian Federation
References
1. Global Strategy for Asthma Management and Prevention, Workshop Report (updated 2011). www.ginashtma. org.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011).
3. Show M. 2-agonists, from pharmacological properties to everyday clinical practice. International workshop report (based on a workshop held in London, UK Feb. 28–29, 2002).
4. Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.
5. Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.
6. Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.
7. Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.
8. Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.
9. Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29
10. Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.
11. Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.
12. Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.
13. Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.
14. Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.
15. Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29.
16. Hockley B., Jonson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.
17. Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism fenoterol, salbutamol // Eur. Respir. J. 1993. №32. Р. 106–111.
18. Сelli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-position paper // Eur. Respir. J. 2004. №23 (6). Р. 932–946.
19. Thompson J., Irvine T., Grathwohl K. et al. Misuse of meter-dose inhalers // Chest. 1994. №105. Р. 715–717.
20. Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices // Resp. Med. 2000. №94. Р. 496–500.
21. Anhoj J., Bisgaard H., Lipwort B.J. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children // Brit. J. Clin. Pharmacol. 1999. №47. Р. 333–336.
22. Chrystyn H. The Discus inhaler. A review of its pharmaceutical and clinical performance // Clin. Drug Invest. 1999. №18. Р. 403–412.
23. Borgstom L.E., Bondesson F., Moren E. еt al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject // Eur. Respir. J. 1994. №7. Р. 69–73.
24. O’Donohue, and the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Guidelines for the use of nebulizers in the home and at domiciliary sites // Chest. 1996. №109. Р. 14.
Review
For citations:
Leschenko IV. Emergency treatment of broncial obstruction diseases in outpatient practice. Meditsinskiy sovet = Medical Council. 2013;(11):50-53. (In Russ.) https://doi.org/10.21518/2079-701X-2013-11-50-53
Views:
338
Email this article 